ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin which completed Phase III clinical trial to treat the negative symptoms of schizophrenia; ACP-101, which completed phase III clinical trial for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 that completed phase II clinical trial for the treatment of Alzheimer's disease psychosis and Lewy Body Dementia with psychosis; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; ACP-211 that is in phase I clinical trial for the treatment of treatment-resistant depression; ACP-2591 that is in Phase I development for Rett syndrome and Fragile X syndrome; and ACP-271, a GPR88 agonist used in evaluation of neurology and is in the IND-enabling stage. The company has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

ACADIA Pharmaceuticals Inc.

An update from AcadeMedia AB ( ($SE:ACAD) ) is now available. AcadeMedia has agreed to acquire all shares in Polish preschool group KIDS&Co., marki...

AcadeMedia enters Polish market with acquisition of KIDS&Co.

Mizuho Securities analyst Uy Ear reiterated a Buy rating on ACADIA Pharmaceuticals yesterday and set a price target of $36.00. The company’s shares...

Mizuho Securities Sticks to Their Buy Rating for ACADIA Pharmaceuticals (ACAD)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Cytokinetics (CYTK), RenovoRx (RNXT) and ACADIA Phar...

Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), RenovoRx (RNXT) and ACADIA Pharmaceuticals (ACAD)

In a report released today, Paul Matteis from Stifel Nicolaus maintained a Hold rating on ACADIA Pharmaceuticals, with a price target of $25.00. Ma...

ACADIA Pharmaceuticals (ACAD) Receives a Hold from Stifel Nicolaus

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Dyne Therapeutics (DYN), ACADIA Pharmaceuticals (ACA...

Analysts Are Bullish on These Healthcare Stocks: Dyne Therapeutics (DYN), ACADIA Pharmaceuticals (ACAD)

In a report released yesterday, Uy Ear from Mizuho Securities reiterated a Buy rating on ACADIA Pharmaceuticals, with a price target of $35.00. Acc...

Mizuho Securities Sticks to Its Buy Rating for ACADIA Pharmaceuticals (ACAD)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Palvella Therapeutics (PVLA), Neogen (NEOG) and ACADIA Pharmaceut...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Palvella Therapeutics (PVLA), Neogen (NEOG) and ACADIA Pharmaceuticals (ACAD)

An announcement from AcadeMedia AB ( ($SE:ACAD) ) is now available. AcadeMedia reported preliminary fourth-quarter 2025/2026 figures showing net sa...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ACAD	$29.21	+2.67%	1.78M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ACAD	$29.21	+2.7%	1.78M
3
4
5
6

ACAD

ACAD

Get ACADIA Pharmaceuticals Inc. Data in Excel

Get ACADIA Pharmaceuticals Inc. Data in Excel